Jurgen Geisler

Summary

Affiliation: Haukeland University Hospital
Country: Norway

Publications

  1. pmc Multilocus analysis of SNP and metabolic data within a given pathway
    Vessela N Kristensen
    Department of Genetics, Institute of Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    BMC Genomics 7:5. 2006
  2. doi request reprint Aromatase inhibitors: from bench to bedside and back
    Jurgen Geisler
    Institute of Medicine, University of Bergen and Department of Oncology, Haukeland University Hospital, Jonas Lies vei, 5021 Bergen, Norway
    Breast Cancer 15:17-26. 2008
  3. ncbi request reprint Aromatase inhibitors as adjuvant treatment of breast cancer
    Jurgen Geisler
    Section of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Crit Rev Oncol Hematol 57:53-61. 2006
  4. ncbi request reprint Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations
    Jurgen Geisler
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 95:75-81. 2005
  5. ncbi request reprint Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
    Jurgen Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Oncol 20:751-7. 2002
  6. ncbi request reprint Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients
    Jurgen Geisler
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 96:415-22. 2005
  7. ncbi request reprint Aromatase inhibition: translation into a successful therapeutic approach
    Jurgen Geisler
    Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 11:2809-21. 2005
  8. doi request reprint Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status
    Jurgen Geisler
    Section of Oncology, Institute of Medicine, University of Bergen, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 118:237-41. 2010
  9. ncbi request reprint Development of aromatase inhibitors and their pharmacologic profile
    Per Eystein Lønning
    Haukeland Hospital, Section of Oncology, Department of Medicine, University of Bergen, Bergen, Norway
    Am J Clin Oncol 26:S3-8. 2003
  10. ncbi request reprint Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels
    Jurgen Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Steroid Biochem Mol Biol 104:27-34. 2007

Collaborators

Detail Information

Publications27

  1. pmc Multilocus analysis of SNP and metabolic data within a given pathway
    Vessela N Kristensen
    Department of Genetics, Institute of Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    BMC Genomics 7:5. 2006
    ..One of the greatest challenges facing human geneticists is the identification and characterization of susceptibility genes for common multifactorial diseases and their association to different quantitative phenotypic traits...
  2. doi request reprint Aromatase inhibitors: from bench to bedside and back
    Jurgen Geisler
    Institute of Medicine, University of Bergen and Department of Oncology, Haukeland University Hospital, Jonas Lies vei, 5021 Bergen, Norway
    Breast Cancer 15:17-26. 2008
    ....
  3. ncbi request reprint Aromatase inhibitors as adjuvant treatment of breast cancer
    Jurgen Geisler
    Section of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Crit Rev Oncol Hematol 57:53-61. 2006
    ..Finally, we need data on cost-utility with respect to the different strategies as well as with respect to patient age and risk profile...
  4. ncbi request reprint Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations
    Jurgen Geisler
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 95:75-81. 2005
    ....
  5. ncbi request reprint Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
    Jurgen Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Oncol 20:751-7. 2002
    ..To compare the effects of the two novel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total-body aromatization and plasma estrogen levels...
  6. ncbi request reprint Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients
    Jurgen Geisler
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 96:415-22. 2005
    ..In contrast, no change in plasma progesterone or 17alpha-hydroxyprogesterone was found. Thus, one possible explanation to our findings could be that DES administered in high doses reduces 17,20-lyase activity in the adrenal gland...
  7. ncbi request reprint Aromatase inhibition: translation into a successful therapeutic approach
    Jurgen Geisler
    Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 11:2809-21. 2005
    ..The need for future translational research exploiting the mechanisms of resistance to these compounds for future improvement of endocrine therapy is emphasized...
  8. doi request reprint Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status
    Jurgen Geisler
    Section of Oncology, Institute of Medicine, University of Bergen, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 118:237-41. 2010
    ..A substantial interindividual variation in the ratios between the individual estrogen fractions suggests additional effects, like alterations in other enzymes to be involved in the intra-tumor estrogen homeostasis...
  9. ncbi request reprint Development of aromatase inhibitors and their pharmacologic profile
    Per Eystein Lønning
    Haukeland Hospital, Section of Oncology, Department of Medicine, University of Bergen, Bergen, Norway
    Am J Clin Oncol 26:S3-8. 2003
    ..Results from in vitro and in vivo studies of AIs suggest that there is variability in efficacy among agents in this class, and the potential clinical implications of these variations are discussed...
  10. ncbi request reprint Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels
    Jurgen Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Steroid Biochem Mol Biol 104:27-34. 2007
    ..These findings suggest that leptin may influence on aromatase activity in vivo, providing a possible link between body weight and plasma estrogen levels as well as breast cancer risk...
  11. doi request reprint An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples
    Jurgen Geisler
    Institute of Medicine, Section of Oncology, University of Bergen, Norway
    J Steroid Biochem Mol Biol 109:90-5. 2008
    ....
  12. doi request reprint Impact of aromatase inhibitors on bone health in breast cancer patients
    Jurgen Geisler
    Institute of Medicine, University of Oslo, Faculty Division at Akershus University Hospital, Sykehusveien 27, N 1478 Lørenskog, Norway
    J Steroid Biochem Mol Biol 118:294-9. 2010
    ....
  13. pmc Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
    Einar Birkeland
    Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
    Clin Exp Metastasis 30:867-76. 2013
    ..013). These findings indicate that BRAF and NRAS expression levels may influence responses to DTIC as well as prognosis in patients with advanced melanoma. ..
  14. ncbi request reprint Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression
    Per E Lønning
    Institute of Medicine and Haukeland University Hospital, University of Bergen, Bergen, Norway
    J Steroid Biochem Mol Biol 108:196-202. 2008
    ....
  15. ncbi request reprint Experience with exemestane in the treatment of early and advanced breast cancer
    Per Eystein Lønning
    Institute of Medicine and Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Expert Opin Drug Metab Toxicol 4:987-97. 2008
    ..Exemestane represents the only steroidal third-generation aromatase inactivator implemented for breast cancer therapy...
  16. ncbi request reprint Indications and limitations of third-generation aromatase inhibitors
    Per Eystein Lønning
    Haukeland University Hospital, Department of Oncology, N 5021, Bergen, Norway
    Expert Opin Investig Drugs 17:723-39. 2008
    ..Use of aromatase inhibitors in postmenopausal breast cancer, initially in advanced disease but recently also for adjuvant therapy, represents a major advance...
  17. pmc Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
    Jennifer Gjerde
    Hormone Laboratory, Haukeland University Hospital, Bergen, N 5021, Norway
    BMC Cancer 10:313. 2010
    ..Here we examined relationships between the serum levels of tamoxifen, estrogens, follicle-stimulating hormone (FSH), and also determined the genotypes of CYP2C19, 2D6, 3A5, and SULT1A1 in 90 postmenopausal breast cancer patients...
  18. doi request reprint MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC
    Christian Busch
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Eur J Cancer 46:2127-33. 2010
    ..The role of MGMT expression as a predictor to DTIC sensitivity versus a general prognostic factor in advanced melanomas warrants further evaluation...
  19. ncbi request reprint Aromatase inhibitors--socio-economical issues
    Per E Lønning
    Department of Medicine, Section of Oncology, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 95:137-42. 2005
    ..The aim of this paper is to overview these considerations and put them into perspective by simple illustrations taken from current cost estimates...
  20. pmc Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
    Inger Marie Løes
    Department of Clinical Science, University of Bergen, Post box 7804, 5021, Bergen, Norway
    Tumour Biol 36:1003-13. 2015
    ..In conclusion, the VE1 antibody is not recommendable for clinical tests of colorectal cancer samples. For melanoma samples, IHC may be useful as a screening tool guiding further analytical approaches...
  21. pmc Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension
    Cornelia Schuster
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    PLoS ONE 7:e38364. 2012
    ..VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of bevacizumab monotherapy in patients with metastatic melanoma...
  22. ncbi request reprint Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer
    Per E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    J Clin Oncol 23:5126-37. 2005
    ..To evaluate potential detrimental effects of exemestane on bone and lipid metabolism...
  23. ncbi request reprint Aromatase inhibitors--socioeconomical issues
    Per E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Department of Oncology, Haukeland Univeristy Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 106:55-61. 2007
    ..For patient groups with a low-risk of relapse but also patients with a limited life expectancy due to high age, cost-utility estimates may exceed the upper limits generally proposed for costs per quality-adjusted life year gained...
  24. ncbi request reprint TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer
    Stephanie Geisler
    Department of Medicine, Section of Oncology, The Gades Institute, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 9:5582-8. 2003
    ..The purpose of this study was to investigate whether TP53 mutational status also might influence the response to a non-anthracycline-containing regimen in primary breast cancer...
  25. ncbi request reprint Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators
    Jurgen Geisler
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 86:245-53. 2003
    ..Moreover, plasma estrogen levels did not correlate with tissue estrogen concentrations. The overall experience with aromatase inhibitors and inactivators concerning their influences on breast tissue estrogen concentrations is summarized...
  26. doi request reprint Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers
    Marianne Hauglid Flågeng
    Department of Clinical Science, University of Bergen, 5021 Bergen, Norway Hormone Laboratory, Haukeland University Hospital, 5021 Bergen, Norway Electronic address
    J Steroid Biochem Mol Biol 165:228-235. 2017
    ..Potential implications to long term sensitivity warrants further investigations...
  27. ncbi request reprint A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family
    Stian Knappskog
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    Genes Chromosomes Cancer 45:1155-63. 2006
    ....